je.st
news
Tag: in
Gap backs annual profit forecast after retailer confirms net income, sales fell in 2Q
2015-08-20 22:49:51| Apparel - Topix.net
Gap is keeping its fiscal-year profit forecast unchanged after further struggles in the second quarter marked by weakness at its namesake and Banana Republic stores that offset rising sales at Old Navy. The San Francisco company also said Thursday its plan to close 175 Gap stores in North America, as well as some locations in Europe, will cost a bit less than it expected.
Riskiest Bank Debt Draws In $6.5 Billion Carnegie Fund in Sweden
2015-08-20 11:21:14| Appliances - Topix.net
Carnegie Fonder AB, a Swedish firm with about $6.5 billion in assets under management, is turning to bank bonds with the highest risk as it searches for better returns. Stockholm-based Carnegie, which oversees almost $3 billion in investment-grade and high-yield assets, says it's buying additional Tier 1 bonds as part of a strategy that targets returns as high as 4 percent in its Swedish krona Corporate Bond fund.
No funding for yet for South Australian farmers in drought
2015-08-20 03:57:55| Livestock - Topix.net
Primary Industries and Regions South Australia's confirmation that parts of the south-east are in drought, without funding allocation for drought action, has raised concern from primary industry leaders. The conflicting messages on whether the State and Federal Governments are aligned on the framework for the drought concessional loans scheme has also caused frustration.
Tags: in
south
funding
australian
Adani negotiating with Softbank and Foxconn to invest in $3bn solar project in India
2015-08-20 01:00:00| Power Technology
Adani Group is holding discussion with Japanese Softbank and Taiwan-based Foxconn to invest in a $3bn solar project, aimed to develop solar cells and panels in India.
First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial In 2017
2015-08-19 07:01:19| drugdiscoveryonline Home Page
The first self-injectable antibody, PRO 140, has documented an impressive 98% success rate in a Phase 2b clinical trial for patients with HIV. In a monotherapy study, some HIV patients using PRO 140 are experiencing a completely suppressed viral load for 11 months.
Tags: in
rate
commercial
trial
Sites : [720] [721] [722] [723] [724] [725] [726] [727] [728] [729] [730] [731] [732] [733] [734] [735] [736] [737] [738] [739] next »